Roth/MKM analyst Jonathan Aschoff reiterated a Buy rating and $11.00 price target on Cyclacel Pharmaceuticals (NASDAQ: CYCC)The analyst comments "Final ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE